COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Utrecht Coronary Biobank (UCORBIO) (UCORBIO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02304744
Recruitment Status : Unknown
Verified March 2015 by Crystel Gijsberts, UMC Utrecht.
Recruitment status was:  Active, not recruiting
First Posted : December 2, 2014
Last Update Posted : March 6, 2015
Information provided by (Responsible Party):
Crystel Gijsberts, UMC Utrecht

Brief Summary:

UCORBIO enrolls patients who undergo coronary angiography (for any indication). The investigators draw blood at the moment of insertion of the procedural arterial catheter.

At the moment of inclusion indication, procedural details, risk factor status, medication use and quality of life (RAND-36 and EuroQoL) is assessed. Patients are then followed-up for the occurrence of major adverse cardiovascular events for 5 years. During the follow-up period patients receive a questionnaire every year to check for hospital admissions. The questionnaires at two and five years of follow-up are enriched with quality of life questionnaires (RAND-36 and EuroQoL).

Condition or disease Intervention/treatment
Coronary Artery Disease Other: Observational study, no intervention.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 3000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Utrecht Coronary Biobank (UCORBIO)
Study Start Date : October 2011
Actual Primary Completion Date : December 2014
Estimated Study Completion Date : December 2019

Intervention Details:
  • Other: Observational study, no intervention.
    Observational study, no intervention.

Primary Outcome Measures :
  1. major adverse cardiovascular events [MACE] (Stroke, myocardial infarction, coronary revascularization, death) [ Time Frame: 5 years ]
    Stroke, myocardial infarction, coronary revascularization, death.

Biospecimen Retention:   Samples With DNA
Whole blood and EDTA plasma.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All adult (>18 years) patients who undergo coronary angiography.

Inclusion Criteria:

  • Coronary angiography

Exclusion Criteria:

  • Age < 18 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02304744

Layout table for location information
UMC Utrecht
Utrecht, Netherlands, 3508GA
Sponsors and Collaborators
UMC Utrecht
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Crystel Gijsberts, MD, UMC Utrecht Identifier: NCT02304744    
Other Study ID Numbers: 11/183
First Posted: December 2, 2014    Key Record Dates
Last Update Posted: March 6, 2015
Last Verified: March 2015
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases